Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients

Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients

Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and safety outcomes in Chinese patients. Given that nivolumab plus chemotherapy has been approved in over 50 countries as a first-line treatment, this updated evaluation assesses whether its benefits remain sustained over time in this population.
ESMO China Voice | Dr. Cheng Huang & Dr. Rongbo Lin: Global First Evidence Shows IV IPCA Outperforms Oral Morphine for Severe Cancer Pain, Potentially Changing Guidelines and Transforming Pain Management

ESMO China Voice | Dr. Cheng Huang & Dr. Rongbo Lin: Global First Evidence Shows IV IPCA Outperforms Oral Morphine for Severe Cancer Pain, Potentially Changing Guidelines and Transforming Pain Management

The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. A Phase III randomized controlled trial (SYLT-021), led by Dr. Rongbo Lin’s team from the Department of Gastrointestinal Oncology, Fujian Cancer Hospital, was selected as one of six Proffered Paper oral presentations in the palliative care session. This study compared hydromorphone intravenous patient-controlled analgesia (IPCA) with oral morphine for severe cancer pain management.
Addressing Hemorrhagic Cystitis in HCT: Insights from Dr. Simone Cesaro on BK Virus Surveillance and Clinical Practice Gaps

Addressing Hemorrhagic Cystitis in HCT: Insights from Dr. Simone Cesaro on BK Virus Surveillance and Clinical Practice Gaps

In this exclusive interview with Infectious Diseases Frontier, Professor Simone Cesaro, a leading expert in pediatric hematology and stem cell transplantation, shares his perspectives on the management of BK polyomavirus-associated hemorrhagic cystitis (HC) following hematopoietic cell transplantation (HCT). Drawing from the findings of a recent EBMT survey, he discusses the clinical implications of passive surveillance strategies, platelet transfusion thresholds, and the urgent need for consensus guidelines to support transplant centers across Europe. His insights underscore the importance of early intervention and standardization in addressing this often-overlooked complication.
EBMT 2025: Opening Ceremony Celebrates Legacy, Innovation, and a Unified Vision for the Future of Transplantation

EBMT 2025: Opening Ceremony Celebrates Legacy, Innovation, and a Unified Vision for the Future of Transplantation

Florence, Italy — March 30, 2025 – The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) commenced in Florence with a compelling and multifaceted opening ceremony that captured the essence of what the EBMT represents. Far beyond a traditional welcome, the evening unfolded as a rich tapestry of scientific achievement, heartfelt remembrance, and forward-looking vision.